A Seoul court approved a rehabilitation plan for Homeplus Co. on Wednesday, Sept. 2, 2026, after creditors and shareholders voted in favor of the proposal. ^[1] A Seoul court approved a corporate rehabilitation plan for Homeplus Co. on Wednesday, allowing the discount store chain to take the first step to revive its operation. ^[2] Beagle Labs, a digital therapeutic device (DTx) specialist and subsidiary of Xperix, announced on September 2, 2026, that it has applied to the Ministry of Food and Drug Safety (MFDS) for approval of its clinical trial plan for the sarcopenia DTx DEX-2. ^[3] MBK Partners Vice Chairman Kim Kwang-il stated that the key to the rehabilitation plan is securing profitability by scaling down the business to focus on profitable stores. ^[4] The plan involves immediately selling some stores to use the proceeds primarily to repay creditors. ^[5] Beagle Labs developed the DEX-2 prototype with support from the Ministry of Trade, Industry and Energy's Biotechnology Industry Development Project, in collaboration with a research team from Bundang Seoul National University Hospital led by Professor Kim Kwang-il and Professors Lim Jae-young and Beom Jae-won. ^[6] This application marks the company's formal entry into the clinical trial and licensing process for the device, with plans to commence formal clinical trials upon MFDS approval and pursue product licensing based on acquired clinical data. ^[7] Beagle Labs is jointly developing a digital fusion drug, DEX-1-OB, combining GLP-1 obesity new drug efglenatide with Hanmi Pharmaceutical, while conducting a pilot study to compare weight loss and muscle preservation effects when used alongside the drug versus drug monotherapy. ^[8]